Gan Shen Fu Fang ameliorates liver fibrosis in vitro and in vivo by inhibiting the inflammatory response and extracellular signal-regulated kinase phosphorylation-Reference-Cited by-同舟云学术

Gan Shen Fu Fang ameliorates liver fibrosis in vitro and in vivo by inhibiting the inflammatory response and extracellular signal-regulated kinase phosphorylation

Published:2020-06-07 Issue:21 Volume:26 Page:2810-2820
ISSN:1007-9327
Container-title:World Journal of Gastroenterology
language:
Short-container-title:WJG

Author:

Du Qing-Hong,Zhang Chu-Jun,Li Wei-Hong,Mu Yan,Xu Ya,Lowe Scott,Han Lin,Yu Xue,Wang Shu-Yan,Li Yu,Li Jian

Publisher

Baishideng Publishing Group Inc.

Subject

Gastroenterology,General Medicine

Reference35 articles.

1. Hepatic fibrosis: Concept to treatment

2. History, Heterogeneity, Developmental Biology, and Functions of Quiescent Hepatic Stellate Cells

3. Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues

4. Pathophysiology of liver fibrosis and the methodological barriers to the development of anti-fibrogenic agents

5. Role of Metabolism in Hepatic Stellate Cell Activation and Fibrogenesis

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative effectiveness of glycyrrhizic acid preparations aimed at improving liver function of patients with chronic hepatitis B: A network meta-analysis of 53 randomized controlled trials;Phytomedicine;2023-07

2. Calcitriol attenuates liver fibrosis through hepatitis C virus nonstructural protein 3-transactivated protein 1-mediated TGF β1/Smad3 and NF-κB signaling pathways;World Journal of Gastroenterology;2023-05-14

3. Current strategies for targeted therapy of liver fibrosis;Bulletin of Siberian Medicine;2022-10-15

4. Salvianolic acid B inhibits autophagy and activation of hepatic stellate cells induced by TGF-β1 by downregulating the MAPK pathway;Frontiers in Pharmacology;2022-08-04

5. Diammonium glycyrrhizinate ameliorates portal hypertension by regulating portal macrophage oxidation and superoxide dismutase 3;European Journal of Pharmacology;2022-08